Plant roots don’t have a nervous system, yet can produce sophisticated responses. What does that say about intelligence?
Get the latest international news and world events from around the world.
No battery needed: Single organic device can act as both indoor solar cell and photodetector
Next-generation optoelectronic systems (devices that convert light to electrical energy) leverage organic semiconductor-based indoor energy-autonomous architectures for cutting-edge applications. Notably, organic semiconductors possess mechanical flexibility, solution processability, and bandgap-tunable optoelectronic properties, making them highly lucrative for indoor power generation via organic photovoltaics (OPVs), as well as for spectrally selective photodetection through organic photodetectors (OPDs). Unfortunately, technological progress made in the fields of OPVs and OPDs has largely been separate, necessitating further research for the development of bifunctional OPV-OPD systems for concurrent energy harvesting and photodetection.
Additionally, the potential self-powered operation of such systems is restricted by conflicting charge transport kinetics, especially in the electron and hole transport layers (ETLs and HTLs, respectively). This limitation impacts device durability and stability and increases fabrication costs, making it indispensable to find new HTL materials such as poly(3,4-ethylenedioxythiophene), 2-(9H-carbazol-9-yl)ethyl]phosphonic acid self-assembled monolayer, MoOx, NiOx, and V2O5, beyond conventional options.
Scientists crack a 20-year nuclear mystery behind the creation of gold
Gold cannot form until certain unstable atomic nuclei break apart. Exactly how those nuclear transformations unfold has long been difficult to determine. Now, nuclear physicists at the University of Tennessee (UT) report three discoveries in a single study that clarify important parts of this process. Their findings could help researchers build improved models of the stellar events that create heavy elements and better predict the behavior of exotic atomic nuclei.
Heavy elements such as gold and platinum are forged under extraordinary conditions, including when stars collapse, explode, or collide. These events trigger the rapid neutron capture process (or r-process for short). During this process, an atomic nucleus absorbs neutrons in rapid succession. As the nucleus grows heavier and more unstable, it eventually breaks down into lighter and more stable forms.
Along this pathway across the nuclide chart, a common sequence involves beta decay of the parent nucleus followed by the release of two neutrons. The atomic nuclei involved in these reactions are extremely rare and unstable, making them difficult or even impossible to study directly in experiments. Because of this, scientists rely heavily on theoretical models, which must be tested and refined using laboratory data.
Ending the Sun’s Monopoly: The Future of Stellarator Fusion — Brian Berzin, CEO, Thea Energy
“with Brian Berzin — Co-Founder & CEO of Thea Energy.
What if we could build a fusion reactor that runs continuously—without the instability issues that have plagued the field for years?
Brian Berzin is the Co-Founder and CEO of Thea Energy (https://thea.energy/), a next-generation fusion company focused on advancing stellarator technology—one of the most promising but historically underexplored approaches to magnetic confinement fusion.
Brian brings a unique combination of deep technical and financial expertise, with a background spanning electrical engineering, venture capital, private equity, and investment banking.
Prior to founding Thea Energy, Brian served as Vice President of Strategy at General Fusion, where he helped shape commercialization strategy and led engagement with global capital markets during a pivotal period for privately funded fusion.
Building the Future of Regenerative Medicine
Imagine treating back pain not with surgery, not with opioids—but by using your own stem cells to repair the damage at its source.
Lance Alstodt is President, CEO, and Chairman of BioRestorative Therapies, Inc. (https://biorestorative.com/), a publicly traded regenerative medicine company focused on developing stem cell-based therapies to treat highly prevalent conditions, including chronic lower back pain and metabolic disorders.
With more than 25 years of experience across healthcare investment banking, medical technology, and company building, Lance brings a unique perspective at the intersection of science and capital markets. Prior to joining BioRestorative, he was the founder and CEO of MedVest Consulting, advising healthcare companies on growth strategy, M&A, and capital formation.
Earlier in his career, Lance held senior leadership roles at firms including Leerink Partners, Oppenheimer & Co., Bank of America Merrill Lynch, and JPMorgan Chase & Co., where he specialized in healthcare and medical technology transactions.
At BioRestorative, Lance is leading the development of innovative cell therapies such as BRTX-100, an autologous mesenchymal stem cell therapy currently in Phase 2 trials for chronic lumbar disc disease, aiming to offer a non-opioid, non-surgical solution to one of the most widespread causes of disability worldwide.
#StemCells #RegenerativeMedicine #BackPainRelief #Biotech #HealthcareInnovation #MedicalBreakthrough #ChronicPain #BioTech #FutureOfMedicine #StemCellTherapy #DegenerativeDiscDisease #PainManagement #HealthTech #BiotechStocks #Longevity #MedicalInnovation #CellTherapy #NonSurgicalTreatment #OpioidCrisis #SciencePodcast #HealthcareRevolution
GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic peptide agonists have several mechanisms of action, including reduction of gastric emptying, inhibition of glucagon secretion, beneficial changes in the intestinal microbiome, and direct effects on hypothalamic nuclei to enhance satiety (which promotes weight loss). Beyond the impressive effects of GLP-1 receptor agonists on blood glucose levels and body weight, large-scale randomized, controlled trials have shown that GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.
World’s largest quantum circuit simulation for quantum chemistry achieved on 1,024 GPUs
A joint research team between the Center for Quantum Information and Quantum Biology (QIQB) at The University of Osaka and Fixstars Corporation has demonstrated one of the world’s largest classical simulations of iterative quantum phase estimation (IQPE) circuits for quantum chemistry on up to 1,024 GPUs, surpassing the previous 40-qubit limit. The result expands the scale of molecular systems available for the development and validation of quantum algorithms for future fault-tolerant quantum computers, supporting progress toward industrial applications in drug discovery and materials development.
The paper was presented at NVIDIA GTC 2026, held in San Jose, California, March 16–19, 2026.
Overcoming unresolved challenges in drug discovery and developing new materials to address climate change will require advanced quantum chemical calculations beyond the reach of current technology. Against this backdrop, fault-tolerant quantum computers (FTQC) are widely anticipated as a key enabling technology, making it increasingly important to develop and validate, ahead of their deployment, the quantum algorithms that will eventually run on such systems.